Editorials

Is it time to abandon RHAMM/HMMR as a candidate antigen for immunotherapy of acute myeloid leukemia?

Institute of Molecular Immunology and Clinical Cooperation Group “Immune Monitoring”, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich, Germany
Vol. 97 No. 10 (2012): October, 2012 https://doi.org/10.3324/haematol.2012.077099